# reload+after+2024-01-21 15:46:53.525673
address1§8000 Jarvis Avenue
address2§Suite 204
city§Newark
state§CA
zip§94560
country§United States
phone§510 953 5559
website§https://www.rainoncology.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.
fullTimeEmployees§63
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Avanish  Vellanki M.B.A.', 'age': 48, 'title': 'Co-Founder, CEO & Chairman', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 959746, 'exercisedValue': 0, 'unexercisedValue': 38584}, {'maxAge': 1, 'name': 'Dr. Robert C. Doebele M.D., Ph.D.', 'age': 52, 'title': 'Co-Founder, Chairman of Scientific Advisory Board, President & CSO and Chief Medical Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 700564, 'exercisedValue': 0, 'unexercisedValue': 359736}, {'maxAge': 1, 'name': 'Ms. Josephine  Bruce', 'age': 44, 'title': 'Principal Financial & Accounting officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Ms. Theresa  O'Connell M.S.", 'title': 'Director of Corporate Development & Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Erik  Atkisson', 'age': 51, 'title': 'General Counsel & Chief Compliance Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Charmi  Turner', 'title': 'Vice President of People & Culture', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Vijaya  Tirunagaru Ph.D.', 'title': 'Senior VP & Head of Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nora  Ku M.D.', 'title': 'MD & VP of Clinical Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§9
compensationRisk§7
shareHolderRightsRisk§10
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.273
currency§USD
dateShortInterest§1702598400
forwardEps§-0.45
exchange§NMS
quoteType§EQUITY
shortName§Rain Oncology Inc.
longName§Rain Oncology Inc.
firstTradeDateEpochUtc§1619184600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d7e2f2aa-12a4-355b-95da-c50965e7eac4
gmtOffSetMilliseconds§-18000000
targetHighPrice§2.0
targetLowPrice§1.0
targetMeanPrice§1.58
targetMedianPrice§1.75
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§3
quickRatio§5.379
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
